Journal article
Clinical Outcomes of Platinum-ineligible Patients with Advanced Urothelial Carcinoma Treated With First-line PD1/L1 Inhibitors
Abstract
BACKGROUND: PD1/L1 inhibitors are approved by FDA as first-line therapy for patients with advanced urothelial carcinoma (aUC) who are cisplatin-ineligible with high tumor PD-L1 expression or are platinum-ineligible regardless of PD-L1 expression. However, the outcomes when employing PD1/L1 inhibitors for platinum-ineligible patients are unclear. This retrospective analysis evaluates the clinical outcomes of first-line PD1/L1 inhibitors in …
Authors
Pond GR; Agarwal A; Ornstein M; Garcia J; Gupta R; Grivas P; Drakaki A; Lee J-L; Kanesvaran R; Lorenzo GD
Journal
Clinical Genitourinary Cancer, Vol. 19, No. 5, pp. 425–433
Publisher
Elsevier
Publication Date
10 2021
DOI
10.1016/j.clgc.2021.04.008
ISSN
1558-7673